Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-64 years (both inclusive) at the time of signing informed consent~* Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Body mass index 18.5-28.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily)~* Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- FIAsp (Type: EXPERIMENTAL): Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
- NovoRapid® (Type: ACTIVE_COMPARATOR): Each subject will be randomised to a treatment sequence consisting of 8 treatment periods

Based on this trial design, predict the completion outcome and termination type (if applicable).